Table 2 Application of the proposed method to Avipiravir® and Artixiban® commercial tablets.
Parameter | Proposed method (I) | Proposed method (II) | |||
|---|---|---|---|---|---|
Amount taken (ng mL−1) | % Recovery a | Amount taken (ng mL−1) | % Recovery * | % Recovery * | |
Avipiravir® (Favipiravir, 200 mg/tab) | 20 | 99.37 | 2 | 98.62 | 98.975 |
40 | 99.79 | 4 | 98.24 | 99.13 | |
60 | 100.56 | 6 | 98.57 | 100.59 | |
– | – | – | – | 99.89 | |
– | – | – | – | 99.41 | |
Mean ± S.D | 99.91 ± 0.60 | 99.48 ± 0.12 | 99.60 ± 0.29 | ||
t | 0.66 (2.47) ** | 2.41(2.47) ** | |||
F | 1.14 (19.25) ** | 10.04(19.25) ** | |||
Artixiban® (Apixaban, 2.5 mg/tab) | 200 | 99.92 | 400 | 100.00 | 100.6818 |
400 | 100.75 | 600 | 98.00 | 98.17311 | |
800 | 100.64 | 800 | 99.13 | 99.27693 | |
– | – | 101.7566 | |||
Mean ± S.D | 100.44 ± 0.46 | 99.04 ± 0.58 | 99.97 ± 1.57 | ||
t | 0.49 (2.57) ** | 0.89(2.57) ** | |||
F | 12.15 (19.16) ** | 2.46(19.16) ** | |||
